The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) last traded at $7.30, up 9.69% from the previous session.
NTLA stock price is now -25.48% away from the 50-day moving average and -56.23% away from the 200-day moving average. The market capitalization of the company currently stands at $755.68M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $30, H.C. Wainwright recently initiated with Buy rating for Intellia Therapeutics Inc (NASDAQ: NTLA). On February 28, 2025, JP Morgan Downgraded its previous ‘Overweight’ rating to ‘Neutral’ on the stock reducing its target price from $45 to quote $13, while ‘Goldman’ rates the stock as ‘Sell’
In other news, Clark Eliana, EVP, Chief Technical Officer sold 679 shares of the company’s stock on Mar 04 ’25. The stock was sold for $6,104 at an average price of $8.99. Upon completion of the transaction, the EVP, Chief Technical Officer now directly owns 95,369 shares in the company, valued at $0.7 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 04 ’25, EVP, General Counsel BASTA JAMES sold 2,572 shares of the business’s stock. A total of $23,122 was realized by selling the stock at an average price of $8.99. This leaves the insider owning 111,925 shares of the company worth $0.82 million. A total of 5.89% of the company’s stock is owned by insiders.
During the past 12 months, Intellia Therapeutics Inc has had a low of $6.59 and a high of $28.18. As of last week, the company has a debt-to-equity ratio of 0.24, a current ratio of 5.77, and a quick ratio of 5.77. The fifty day moving average price for NTLA is $9.7957 and a two-hundred day moving average price translates $16.677025 for the stock.
The latest earnings results from Intellia Therapeutics Inc (NASDAQ: NTLA) was released for 2024-12-31. The net profit margin was -896.77% and return on equity was -54.00% for NTLA. The company reported revenue of $12.87 million for the quarter, compared to -$1.92 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -771.57 percent.
